LEVELJUMP HEALTHCARE CP - JMPHF STOCK NEWS

LevelJump Healthcare Corp (TSXV: JUMP) reported its Q2 2024 financial results, showing significant growth. Key highlights include:

- Canadian Teleradiology Services (CTS) revenues reached $4.4 million, a 42% year-over-year increase.

- Consolidated net income was $179,316 for Q2, with a year-to-date net loss of $(322,039).

- Q2 EBITDA was $655,484, with year-to-date EBITDA of $757,344.

CEO Mitch Geisler noted that the company is now tracking over $16 million annually in revenues, with expectations to grow to over $20 million as the Yonge Sheppard location opens. Gross margins are projected to reach 20% or more.

LevelJump Healthcare Corp. (TSXV: JUMP) has released its Q1 2024 financial results, highlighting strong revenue growth. Key points include:

- Canadian Teleradiology Services (CTS) revenues reached $4.1 million, a 46% year-over-year increase
- Consolidated net loss of $(501,480)
- Consolidated EBITDA of $97,742

CEO Mitch Geisler noted that the company is now tracking over $16 million annually in revenues. With the opening of the Yonge Sheppard location, LevelJump anticipates revenues to grow to over $20 million annually, with consistently positive EBITDA. The company uses non-IFRS financial measures like adjusted EBITDA to evaluate operating performance and liquidity.

LevelJump Healthcare Corp. (TSXV: JUMP) reported its 2023 financial results, highlighting a 36% year-over-year revenue increase to $12.6 million for its Canadian Teleradiology Services (CTS) subsidiary. The company's Q4 2023 revenues were $3.9 million, with a net loss of $(216,708). For the full year 2023, LevelJump reported a net loss of $(2,208,117), while CTS achieved a net profit of $1 million.

Key highlights include:

• Acquisition of 4 Independent Healthcare Facilities in Calgary, Alberta
• Q4 2023 EBITDA of $290,920 and Adjusted EBITDA of $340,920
• Full-year 2023 EBITDA of $(221,329) and Adjusted EBITDA of $78,671

LevelJump's management expects continued growth in 2024, focusing on completing its new Yonge Sheppard Center clinic and integrating the Alberta acquisition.

LevelJump Healthcare Corp. (TSXV: JUMP) announced the acquisition of a pre-1954 pharmacy charter for $1,900,000, enhancing its telehealth solutions. The purchase includes $1,800,000 in cash and 100,000 shares of JUMP preferred shares. The CEO, Mitch Geisler, anticipates integrating pharmacy services into the teleHospital portal to provide a comprehensive healthcare package to patients and boost revenues.

LevelJump Healthcare Corp. (TSXV: JUMP) announces that its application for a management cease trade order has been denied by the Ontario Securities Commission, leading to a potential Failure to File Cease Trade Order. The delay in filing its annual financial statements is attributed to a change in auditors and extensive audit work related to acquisitions in Alberta. Despite the impending trading suspension, the company remains focused on its strategic objectives.

LevelJump Healthcare Corp. (JMPHF) announces a delay in filing its year-end financial documents due to a change in auditors and a large amount of audit work related to acquisitions. The company expects to file the documents no later than June 28, 2024, and has applied for a management cease trade order to address the default.

LevelJump Healthcare Corp. (JMPHF) announces enhancements at its Diagnostic Imaging Centres in Alberta, including pain management treatments, extended X-ray hours, additional ultrasound machines, marketing efforts, and EMR system upgrades.

LevelJump Healthcare Corp. (JMPHF) anticipates a 30% revenue increase for its subsidiary CTS, expanded operations in Canada, acquisitions of diagnostic imaging clinics, upcoming flagship clinic, teleHospital development, Teleradiology services expansion, settlement with RTM, and update on private placement.

LevelJump Healthcare Corp. announces an extension for its proposed non-brokered private placement, offering up to 5,000,000 units at $1.00 per unit for gross proceeds of up to $5,000,000. The company has sold 1,955,000 units and 2,094,000 Class A-1 Preferred shares to date. The Preferred shares are capped at a maximum of 10,000,000 shares that can be issued. Each Unit will consist of one common share and one 12% cumulative redeemable convertible Class A Series 1 preferred share. The Company is also offering a finders fee of 7%. The Offering is conditional upon receipt of all required regulatory approvals, including the approval of the TSX Venture Exchange.